US Scientists: A New Vaccine Might Can Contain HIV Infection

AIDS is a great danger of infectious disease, caused by the HIV virus. HIV is a human immune system to attack the virus. It is the body's most important immune system T cells as the main target, a lot of damage to the cells, the loss of human immune function. Therefore, the body susceptible to infection with various diseases, and malignant tumors, mortality is higher. HIV in the human body average incubation period of 8-9 years, before AIDS, may not have any symptoms for many years to live and work.

US "Science" and "Cell" published two studies on the 18th of view, based on several rounds of vaccination strategies experimental vaccines, may have the potential to curb HIV infection.

Based on several rounds of vaccination strategies experimental vaccines, may have the potential to curb HIV infection.

Traditional vaccines work of thinking is the use of inactivated version of the virus to stimulate the body to produce antibodies. However, the use of "natural" development of a vaccine for HIV proteins can not elicit an effective immune response, which is due to the AIDS virus can evade the immune system to detect and quickly mutate into a new virus strain.

These two studies suggest that a successful HIV vaccine needs to include a series of related but slightly different immunogens, after several rounds of immunization can stimulate the body to produce broadly neutralizing anti-HIV antibodies. This is the traditional "enhanced vaccine" thinking different from the traditional idea is to make the same number of contacts vaccinated immunogen.

Both studies are all about something called "eOD-GT8 60mer" immunogen. Scripps Research Institute and other institutions it has been tested, the results show that it can bind to and activate B cells, and B cells with anti-HIV effect. Both studies used two different mouse models, the results show there is hope in this immunogen based on the development of an effective AIDS vaccine.

"Science" magazine also published a study conducted by Cornell University AIDS led the third, on an artificial molecule complex the test results show that the immunogen can stimulate the production of antibodies rabbits and monkeys to prevent an HIV strain infection.

US National Institutes of Health for these three studies provide the funding, it said in a statement commented that these three papers represent in the development of HIV vaccines, "an important new starting point."